Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2026 /CourierPR/ -- Editas Medicine, a leading gene editing company, will participate in two upcoming investor conferences in September to discuss its advancements and future plans in developing transformative treatments for serious diseases.

At the Wells Fargo Healthcare Conference, scheduled for Tuesday, September 8, at 4:30 p.m. Eastern Time in Boston, Massachusetts, company management will deliver a fireside chat. Interested parties can access the live webcast through the "Investors" section of Editas Medicine’s website. An archived version will be available for approximately 30 days post-conference.

The company will also present at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, at 3:55 p.m. Eastern Time, in New York City. The format will again be a fireside chat, offering investors and stakeholders the opportunity to hear directly from Editas Medicine’s leadership.

Editas Medicine is dedicated to leveraging the power of CRISPR genome editing to create innovative, in vivo gene editing medicines for a wide range of serious diseases. The company aims to discover, develop, manufacture, and commercialize these medicines, focusing on delivering durable and precise treatments for patients worldwide.

With its exclusive license to Broad Institute’s Cas12a and Cas9 patent estates for human medicines, Editas Medicine is well-positioned to advance its research and development efforts. For the latest updates and scientific insights, the public can visit the company’s website, www.editasmedicine.com.